Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dr Reddy’s Laboratories ( (RDY) ) has shared an update.
On July 24, 2025, Dr. Reddy’s Laboratories announced that its shareholders approved the appointment of Makarand M. Joshi & Co. as the Secretarial Auditors for a five-year term starting April 1, 2025. This decision, made during the company’s 41st Annual General Meeting, underscores Dr. Reddy’s commitment to maintaining robust corporate governance practices, potentially enhancing its credibility and operational transparency in the pharmaceutical industry.
The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.
The overall stock score of 68 reflects strong financial performance and reasonable valuation, offset by bearish technical indicators. The company’s solid balance sheet and consistent revenue growth bolster its financial health, but short-term market momentum suggests caution.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a prominent pharmaceutical company based in Hyderabad, India. The company is known for its production of generic medications, active pharmaceutical ingredients, and biosimilars, with a focus on providing affordable healthcare solutions globally.
Average Trading Volume: 1,584,757
Technical Sentiment Signal: Strong Buy
Current Market Cap: $12.05B
For detailed information about RDY stock, go to TipRanks’ Stock Analysis page.